Health Catalyst, Inc. (NASDAQ:HCAT) Receives $11.42 Average Price Target from Analysts

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have earned an average recommendation of “Moderate Buy” from the twelve research firms that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $11.42.

A number of research analysts have commented on HCAT shares. Piper Sandler lowered their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. Evercore ISI dropped their price objective on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research note on Tuesday, August 20th. Canaccord Genuity Group restated a “buy” rating and set a $11.00 price target on shares of Health Catalyst in a research note on Tuesday, May 21st. Finally, JPMorgan Chase & Co. raised their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th.

Health Catalyst Price Performance

NASDAQ:HCAT opened at $8.70 on Wednesday. The stock has a market cap of $513.60 million, a PE ratio of -4.70 and a beta of 1.31. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The stock’s 50-day moving average is $7.14 and its two-hundred day moving average is $6.89.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. The firm had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The firm’s revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.21) earnings per share. On average, equities research analysts anticipate that Health Catalyst will post -0.35 earnings per share for the current year.

Insider Buying and Selling

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, COO Daniel Lesueur sold 5,208 shares of the stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $6.15, for a total value of $32,029.20. Following the completion of the sale, the chief operating officer now owns 155,215 shares in the company, valued at $954,572.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,037 shares of company stock valued at $236,872. Insiders own 2.70% of the company’s stock.

Institutional Trading of Health Catalyst

A number of hedge funds have recently modified their holdings of HCAT. Nisa Investment Advisors LLC lifted its position in Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares during the period. Quarry LP lifted its holdings in shares of Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after acquiring an additional 2,610 shares during the period. Perfromance Wealth Partners LLC acquired a new stake in shares of Health Catalyst during the 2nd quarter valued at about $64,000. Mackenzie Financial Corp bought a new stake in Health Catalyst in the second quarter valued at about $70,000. Finally, EntryPoint Capital LLC acquired a new position in Health Catalyst in the first quarter worth about $98,000. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.